26 results about "Lipoxin" patented technology

The present invention relates to high density lipoprotein (HDL) or HDL mimetics for use in the prevention and / or treatment of graft-versus-host disease (GvHD) or cytokine release syndrome in a subject.

The invention provides application of a mucolipoprotein transient receptor potential channel 1 as a target spot in preparation of a medicine for treating pulmonary arterial hypertension, and belongs to the technical field of biological medicine manufacturing. The invention relates to application of a mucolipoprotein transient receptor potential channel 1 (TRRP Mucipin1, TRPML1) as a target spot in preparation, development or screening of a medicine for treating pulmonary hypertension (PH), in particular to application of the medicine in preparation, development or screening of the medicine for treating the PH. The invention also provides application of a reagent 1 for up-regulating smooth muscle cell Mcoln1 gene and / or smooth muscle cell TRPML1 protein expression or a reagent 2 for improving smooth muscle cell TRPML1 protein activity in preparation of drugs for treating PH. Experiments show that the over-expressed TRPML1 in the smooth muscle affects the PH pulmonary vascular remodeling process and PH generation and development through autophagy regulation and control, and the purpose of PH treatment is achieved.

This application discloses the application of pyridostigmine in the preparation of drugs for the prevention and treatment of non-alcoholic fatty liver disease (NAFLD). Validation was conducted using animal models of NAFLD induced by three different etiologies: methionine-choline deficiency diet, high-fat diet, and leptin gene knockout. Pyridostigmine significantly improved vagal nerve activity in the model animals (e.g., improving high-frequency and baroreflex sensitivity in heart rate variability), effectively corrected serum lipid metabolism disorders (reducing LDL cholesterol), alleviated hepatocyte damage (reducing ALT and AST), and at the histopathological level, reduced hepatic steatosis, decreased inflammatory cell infiltration, and inhibited collagen deposition, thereby achieving the prevention and treatment of NAFLD.

Disclosed herein are methods of disease treatments by administering to a subject in need thereof a pharmaceutical composition comprising gene editing compositions. The methods disclosed herein can provide durable in vivo editing of PCSK9. More particularly, the compositions disclosed herein are capable of in vivo editing PCSK9 gene in humans and reducing PCSK9 protein and LDL-C for a potentially transformative treatment of cardiovascular disease, the leading cause of death in the United States and world-wide. Various aspects of the compositions, use and preparation are disclosed, including clinically supported therapeutically effective and safe human dosing of the compositions.

Provided herein are cyclic prosaposin peptides and compositions and uses thereof. Exemplary uses include use in the treatment of cancer or in the treatment of inflammatory diseases or disorders.

The invention belongs to the technical field of disease detection and health examination, and particularly relates to an enzyme-linked immunosorbent assay method of apolipoprotein E and application of the apolipoprotein E in glaucoma diagnosis. A capture antibody used by the kit is 1D4, a heavy chain variable region of the capture antibody comprises HCDR1-3 as shown in SEQ ID NO: 4-6, and a light chain variable region of the capture antibody comprises LCDR1-3 as shown in SEQ ID NO: 1-3; a detection antibody used by the kit is 3A6, a heavy chain variable region of the detection antibody comprises HCDR1-3 as shown in SEQ ID NO: 12-14, and a light chain variable region of the detection antibody comprises LCDR1-3 as shown in SEQ ID NO: 9-11. The double-antibody sandwich ELISA detection kit for detecting ApoE4 provided by the invention has no cross reaction with other subtypes of ApoEs, the used monoclonal antibody has high sensitivity, the kit can be used for screening glaucoma in physical examination and ophthalmic examination of old people, and the screening result is counted and summarized to a health information system and a cloud platform for big data analysis, so that the health condition of a patient can be detected.

The present disclosure provides a technique for simply, rapidly, and visually detecting modified LDL or stimulating AGEs. The present disclosure also provides a device or kit for detecting or quantifying an abnormal type of a biomarker molecule by forming a conjugate with the biomarker molecule, the device or kit comprising a membrane for developing a sample by utilizing a capillary action, wherein the membrane comprises: a detection part including a binding agent for detection which binds specifically to the biomarker molecule or a competitor molecule thereof; and a control part including a binding agent for control which binds specifically to a binding molecule having conjugate-forming ability with the abnormal type of the biomarker molecule or a competitor molecule thereof, and the kit or device comprises a sample contact part and a metal colloid as portions of the membrane or separate elements.

The invention provides application of barley pest larva defatted protein powder in preparation of drugs for treating inflammatory bowel diseases. The invention belongs to the technical field of medicine, and by establishing a dextran sodium sulfate induced mouse IBD model and lavaging barley pest larva defatted protein powder, it is found that the traditional Chinese medicine composition can relieve IBD mouse colitis symptoms, restore colon length, relieve mucosal lesion, retain goblet cell and crypt structures, reduce inflammatory cell infiltration and down-regulate inflammatory cytokine expression; the compound is expected to play an important role in preparing medicines for treating inflammatory enteritis.

Methods and materials for preventing and modulating atherosclerosis. In particular, small peptides that are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD154, which impacts inflammation and atherosclerosis. The use of such peptides in reducing atherosclerosis, and in particular, the autoimmune inflammatory response that may be a driving factor thereof. The use of such short peptides to lower LDL cholesterol. Methods and materials for detecting T-cells that express CD40 (Th40 cells). Methods and materials for preventing, modulating, reducing and / or reversing type 2 diabetes and auto-inflammatory disease. In particular, small peptides that are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD154, which impacts inflammation and type 2 diabetes. The use of such peptides in reducing type 2 diabetes, and in particular, the autoimmune inflammatory response that may be a driving factor thereof. The use of such short peptides to lower IL2, INFγ, and IL17a. The use of such peptides to increase glucose transport protein (GLUT4). Methods and materials for detecting T-cells that express CD40 (Th40 cells).

To provide an improved method for treating IdiopathicPulmonaryFibrosis (IPF).SOLUTION: The invention features a polypeptide comprising a variant of plasminogen-activator inhibitor-1 (PAI-1) having a reduced capacity to bind vitronectin, a reduced capacity to interact with the PAI-1 clearance receptor LDL-receptor-related-protein 1 (LRP1), and a capacity to efficiently inhibit neutrophil elastases in presence of neutrophil extracellular traps (NETs). In some embodiments, a polypeptide of the present invention comprises a PAI-1 variant optionally fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions characterized by aberrant neutrophil elastase activity (as an example, idiopathic pulmonary fibrosis).SELECTED DRAWING: Figure 1

The invention belongs to the technical field of biology, and particularly relates to a composite peptide capable of improving animal immunity and a preparation method of the composite peptide, and the composite peptide is formed by compounding InflamBlock-9 peptide and ImunoEnhance-7 peptide according to the mass ratio of 3: 1. Wherein the InflamBlock-9 peptide is used for reducing excessive secretion of proinflammatory factors IL-1beta, IL-6 and TNF-alpha through targeted inhibition of an NF-kappa B signal channel key protein Ikappa B kinase (IKK); the ImmunoEnhance-7 peptide is used for promoting the synthesis of immune globulins IgG (Immunoglobulin G) and IgA (Immunoglobulin A) and apolipoprotein A1 (Apo-A1) by activating a JAK-STAT (JavaScript Activated Amplification) signal channel. The combined use of the two can significantly reduce the levels (Plt, 0.05) of IL-1beta, IL-6 and SAA in the serum of cats in a stress state, improve the contents (Plt, 0.05 or Plt, 0.10) of IL-10, IgG and Apo-A1, and effectively relieve the inflammatory overexpression and improve the immunosuppression state. According to the preparation method, efficient preparation of the polypeptide is achieved through a prokaryotic and eukaryotic dual-expression system, the process is controllable, cost is low, and the preparation method is suitable for development of functional food or health care products for pets.

The application belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody combination for detecting apolipoprotein E4 and application thereof. The combination comprises monoclonal antibody 4E10 and monoclonal antibody 3H7, and the complementarity determining region (CDR) sequences thereof are shown as SEQ ID NO. 1 to SEQ ID NO. 12. In a double antibody sandwich ELISA, 4E10 is used as a coating antibody, and 3H7 is used as a labeled antibody, so that APOE4 subtypes can be effectively recognized, high specificity and high sensitivity detection of APOE4 can be realized, the detection limit reaches 100 pg / mL, and the method is suitable for quantitative detection of APOE4 in serum, cerebrospinal fluid and the like. The method provides a reliable immunological tool for early risk assessment of Alzheimer's disease, and has important clinical application value.

Provided herein, among other things, are novel and improved glycoproteins, including modified glycoproteins; engineered viral particles comprising such novel and modified glycoproteins; and methods for targeted delivery, for example, to immune cells such as T cells. In some aspects, the engineered viral particles allow targeted delivery of the cargo for various applications, including treating various conditions such as autoimmune diseases and cancer. In some aspects, the engineered viral particles comprise a viral fusogen that is a glycoprotein of Chandipura, Perinet, Piry, Jurona viruses, or variants thereof. In other aspects, the engineered viral particles comprise a modified vesiculovirus glycoprotein mutant, for example, with mutations at amino acids corresponding to positions I347 or R354 of Vesicular Stomatitis Virus G (VSV-G) that reduce binding to Low Density Lipoprotein Receptor (LDL-R).

A method of preventing or treating or controlling a respiratory disease in a bovine by delivering to a lung or trachea of the bovine a composition including a polyplex having one or more mRNA encoded with a molecule selected from lycosylphosphatidylinositol (GPI) complex, antibody immunoglobulin G (IgG), antibody immunoglobulin A (IgA), antibody immunoglobulin M (IgM), antimicrobial peptide Bactenecin 5 (Bac5), antimicrobial peptide Bactenecin 7 (Bac7), bovine myeloid antimicrobial peptide (BMAP-28), lipoxin inducing enzymes, resolvin inducing enzymes, cytokines, CRISPR associated protein 13 (Cas13) enzymes, nanoluciferase (NLuc) proteins, and gene activator, catalytically dead CRISPR-associated protein 9 fused to an activator selected from the group consisting of VP64-p65-Rta transactivation domain (dCas9-VPR), VP64, and VP64-p65-HSF1 on the N terminus and SS18 on the C-terminus, and a polymer prepared by polymerizing a diacrylate monomer; one or more linker monomers; and one or more branching monomers; and end-capping the polymer.

Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of PLP1 RNA in a cell or subject, and in certain instances reducing the amount of proteolipid protein 1 in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a leukodystrophy. Such symptoms and hallmarks include hypotonia, nystagmus, optic atrophy, respiratory distress, motor delays, cognitive dysfunction, speech dysfunction, spasticity, ataxia, seizures, choreiform movements, and death. Such leukodystrophies include Pelizaeus-Merzbacher disease.

The present invention provides compositions and methods for treating cancer in a subject by administering to the subject an antibody or fragment thereof that binds to oxidized LDL. In some embodiments, the compositions and methods may reduce the size of the tumor, reduce macrophage infiltration, and / or inhibit metastasis.

The present disclosure provides a technique for quantitatively detecting denatured LDL or stimulative AGEs in a quick and easy manner. The present disclosure also provides a device or kit for detecting or quantizing aberrant forms of biomarker molecules by forming a conjugate with the biomarker molecules, the device or kit including a membrane that carries out development of a specimen due to a capillary phenomenon, wherein: the membrane includes a detection part including a detection binding agent that specifically binds to the biomarker molecules or to competing molecules thereof, and a control part including a control binding agent that specifically binds to bound molecules and has a function for forming a conjugate with aberrant forms of the biomarker molecules or with competing molecules thereof; and the device or kit includes a specimen contact part and fluorescent nanoparticles as part of the membrane or as separate elements.

Provided herein, among other things, are novel and improved glycoproteins, including modified glycoproteins; engineered viral particles comprising such novel and modified glycoproteins; and methods for targeted delivery, for example, to immune cells such as T cells. In some aspects, the engineered viral particles allow targeted delivery of the cargo for various applications, including treating various conditions such as autoimmune diseases and cancer. In some aspects, the engineered viral particles comprise a viral fusogen that is a glycoprotein of Chandipura, Perinet, Piry, Jurona viruses, or variants thereof. In other aspects, the engineered viral particles comprise a modified vesiculovirus glycoprotein mutant, for example, with mutations at amino acids corresponding to positions I347 or R354 of Vesicular Stomatitis Virus G (VSV-G) that reduce binding to Low Density Lipoprotein Receptor (LDL-R).

The disclosure relates to the field of diseases caused by high levels of LDL-C and / or fibrinogen, such as cardiovascular disease (CVD). The disclosure involves antisense oligonucleotides (AONs) for RNA editing technology in deaminating a specific adenosine in transcript molecules of the human Asparagine-Linked Glycosylation 12 homolog glycosyltransferase (ALG12) gene, thereby rendering a mutation from a serine residue at position 275 in the human ALG12 amino acid sequence to a glycine residue (S275G).

The disclosure relates, in some aspects, to compositions and methods for treatment of diseases associated with aberrant lysosomal function, for example Parkinson's disease and Gaucher disease. In some embodiments, the disclosure provides expression constructs comprising a transgene encoding beta-Glucocerebrosidase (GBA) or a portion thereof, Lysosomal Membrane Protein 2 (LIMP2), Prosaposin, or any combination of the foregoing. In some embodiments, the disclosure provides methods of Parkinson's disease by administering such expression constructs to a subject in need thereof.

The invention discloses a marker group for evaluating sensitivity of bicitinib combined with narrow-spectrum medium-wave ultraviolet rays in treatment of leucoderma, a substance for detecting the marker group, a kit and an evaluation method. The marker group contains a plasma biomarker P selectin (SELP), an apolipoprotein A4 (APOA4), a mannan binding lectin associated serine protease 1 (MASP1), and a urine biomarker immune globulin J chain (IGJ) and an interleukin 18 binding protein (IL-18BP). By detecting the expression change of the group of markers in a sample before and after treatment and combining with a vitiligo area scoring index (VASI), the treatment sensitivity of a patient can be accurately evaluated, an individualized scheme can be made in an assisted manner, the blank of the combination therapy curative effect evaluation marker is filled, and the combination therapy curative effect evaluation marker has a relatively high clinical transformation value.

The present invention relates to a composition for the prevention, improvement, or treatment of obesity or obesity-induced inflammation comprising patulin as an active ingredient. A composition containing patulin as an active ingredient according to the present invention has the effect of inhibiting lipid accumulation, and can inhibit lipid accumulation by regulating sugar absorption, glycerol excretion, or LDL absorption, reducing the expression of factors related to lipogenesis or lipid synthesis such as Pparγ, Fasn, Acly, C / ebpα, Fabp4, Cd36, Dgat2, or Gpat, increasing the expression of fatty acid oxidation regulators such as PGC1α or CPT1a, and improving the volume and membrane potential of mitochondria. In addition, it can inhibit the expression of pro-inflammatory cytokines or inflammatory regulators such as IL-6, TNF-α, iNOS, or Cox-2, thereby preventing, treating, or improving obesity or obesity-induced inflammation, and can be utilized as a material for food, feed, pharmaceuticals, quasi-pharmaceuticals, etc.

A method of assessing the risk for development of cardiovascular disease (CVD) or an inflammatory disease in a patient comprises (i) incubating a sample of body fluid with donor particles, wherein the donor particles are coated with a lipid and a first quantity of detectably labeled, non-exchangeable lipid probe (NELP); (ii) separating the detectably labeled NELP-associated HDL into a first portion and the donor particles into a second portion; (iii) measuring the second quantity of detectably labeled NELP in the first portion; (iv) determining a detectably labeled NELP efflux value for the patient; and (v) comparing the detectably labeled NELP efflux value for the patient to a reference standard. Related methods of lowering the risk for development of CVD or an inflammatory disease in a patient and methods of measuring the quantity of functional HDL in a sample of body fluid are also provided.

The present application relates to the biomedical field, and particularly to a clinical marker for monitoring CRS progress after CAR-T treatment and application thereof, the cytokine release syndrome (CRS) progress is judged by the expression of apolipoprotein A-1, so that effective treatment can be carried out and new treatment methods can be developed. The present application discloses APOA1 for the first time to monitor the cytokine release syndrome (CRS) progress after CAT-T treatment, and it is found through mass spectrometry and biochemical detection that APOA1 is expressed the lowest when the inflammation of the cytokine release syndrome (CRS) patient is the most serious, and with the recovery of the inflammation, its expression is also gradually recovered to the pre-treatment, and the cytokine release syndrome (CRS) progress of the patient has good consistency. These results suggest that APOA1 is an important clinical indicator for monitoring the cytokine release syndrome (CRS).

Provided herein are compositions and methods for the delivery of prosaposin and saposins within the tumor microenvironment in order to enhance anti-tumor immunity.

The present invention relates to a polyherbal compound based formulation for managing hypertension and related disorders, comprising Dioscin, Withanolide A, Withaferin A, Withanolide D, P-Sitosterol, Diosgenin, Arjunolic Acid, Caffeic Acid, and Kaempferol. The compounds targets multiple mechanistic pathways in hypertension, including the Renin- Angiotensin-Aldosterone System (RAAS), Sympathetic Nervous System, Vascular Resistance, Nitric Oxide, and Stress-Responsive pathways. It offers a comprehensive and synergistic approach for improving vascular health, reducing blood pressure, regulating the levels of HDL and lowering of Cholesterol, LDL and Triglycerides. The compound / s is formulated for enhanced bioavailability and efficacy, and can be used as an adjuvant with antihypertensive agents. The invention also includes methods for extracting, purifying, and standardizing the active ingredients, ensuring consistent quality. The compounds is suitable for managing hypertension, cardiovascular diseases, metabolic disorders, and stress. It can be administered in various dosage forms such as tablets, capsules, syrups, and powders.